Original BioMedicals Co., Ltd. (TPEX:6483)

Original BioMedicals Income Statement

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	0.04	0.11	-	-
Revenue Growth (YoY)	-	-59.81%	-	-	-
Cost of Revenue	-	0.01	0.01	-	-
Gross Profit	-	0.04	0.1	-	-
Selling, General & Admin	45.28	34.59	17.36	11.92	11.68
Research & Development	33.05	24.71	22.91	20.74	22.06
Operating Expenses	78.33	59.3	40.27	32.67	33.74
Operating Income	-78.33	-59.26	-40.18	-32.67	-33.74
Interest Expense	-0.87	-1.07	-1.2	-1.39	-1.56
Interest & Investment Income	4.19	0.7	0.47	0.14	0.01
Currency Exchange Gain (Loss)	0.01	-0	0	-0	-0
Other Non Operating Income (Expenses)	-	-0.03	0.62	0.04	0.55
EBT Excluding Unusual Items	-75	-59.66	-40.28	-33.88	-34.75
Pretax Income	-75	-59.66	-40.28	-33.88	-34.75
Net Income	-75	-59.66	-40.28	-33.88	-34.75
Net Income to Common	-75	-59.66	-40.28	-33.88	-34.75
Shares Outstanding (Basic)	66	49	47	42	28
Shares Outstanding (Diluted)	66	49	47	42	28
Shares Change (YoY)	33.68%	4.87%	13.05%	50.66%	15.49%
EPS (Basic)	-1.14	-1.21	-0.86	-0.81	-1.26
EPS (Diluted)	-1.14	-1.21	-0.86	-0.81	-1.26
Free Cash Flow	-85.95	-27.81	-30.89	-26.86	-23.94
Free Cash Flow Per Share	-1.30	-0.56	-0.66	-0.65	-0.87
Gross Margin	-	81.39%	88.78%	-	-
Operating Margin	-	-137818.61%	-37547.66%	-	-
Profit Margin	-	-138746.51%	-37642.06%	-	-
Free Cash Flow Margin	-	-64674.42%	-28864.49%	-	-
EBITDA	-74.05	-54.64	-35.64	-27.43	-25.26
D&A For EBITDA	4.29	4.62	4.54	5.24	8.48
EBIT	-78.33	-59.26	-40.18	-32.67	-33.74

Source: S&P Global Market Intelligence. Standard template. Financial Sources.